LLAI vs. GENI, DMTR, LLA, IDHC, DXRX, AGL, YGEN, ABDX, PRM, and GDR
Should you be buying LungLife AI stock or one of its competitors? The main competitors of LungLife AI include GENinCode (GENI), Deepmatter Group (DMTR), LLA.L,0P0001T9GN,0 (LLA), Integrated Diagnostics (IDHC), Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), and genedrive (GDR). These companies are all part of the "diagnostics & research" industry.
LungLife AI vs.
LungLife AI (LON:LLAI) and GENinCode (LON:GENI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
In the previous week, GENinCode had 1 more articles in the media than LungLife AI. MarketBeat recorded 1 mentions for GENinCode and 0 mentions for LungLife AI. GENinCode's average media sentiment score of 0.75 beat LungLife AI's score of 0.00 indicating that GENinCode is being referred to more favorably in the news media.
GENinCode has a net margin of -228.70% compared to LungLife AI's net margin of -15,403.45%. LungLife AI's return on equity of -56.38% beat GENinCode's return on equity.
42.5% of LungLife AI shares are held by institutional investors. Comparatively, 47.6% of GENinCode shares are held by institutional investors. 48.4% of LungLife AI shares are held by company insiders. Comparatively, 39.8% of GENinCode shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
LungLife AI and GENinCode both received 0 outperform votes by MarketBeat users.
LungLife AI has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Comparatively, GENinCode has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
LungLife AI has higher earnings, but lower revenue than GENinCode. GENinCode is trading at a lower price-to-earnings ratio than LungLife AI, indicating that it is currently the more affordable of the two stocks.
Summary
GENinCode beats LungLife AI on 7 of the 13 factors compared between the two stocks.
Get LungLife AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LungLife AI Competitors List
Related Companies and Tools
This page (LON:LLAI) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy LLAI Stock Free LLAI Stock Alerts